Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Arena's lorcaserin reduces body weight across patient subgroups

Arena's lorcaserin reduces body weight across patient subgroups

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Risk, incidence of VTE differs between races

Risk, incidence of VTE differs between races

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

Risk of MI increases six-fold in young women with RA: Study

Risk of MI increases six-fold in young women with RA: Study

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Roche implements risk mitigation plan in taspoglutide Phase III programme

Roche implements risk mitigation plan in taspoglutide Phase III programme

Review of possible uses, limits of WB-MRI procedure

Review of possible uses, limits of WB-MRI procedure

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

Patients prescribed NSAIDs also receive appropriate measures to prevent UGI problems: Study

Patients prescribed NSAIDs also receive appropriate measures to prevent UGI problems: Study

Harbor BioSciences closes $2.06M common stock registered direct offering

Harbor BioSciences closes $2.06M common stock registered direct offering

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.